Further Comments on the Alpha Spending Function
- 239 Downloads
The use of alpha spending functions has become a powerful tool in designing group sequential trials since 1990. In this manuscript, we present practical problems we encountered and suggest possible solutions. Since group sequential methods deal with only one endpoint, they have certain intrinsic limitations in medical research. As a result, we often modify the design in conducting clinical trials since the sequential statistical framework is not sophisticated enough to handle many practical problems related to multiple endpoints in clinical trials. Topics discussed include the choice of a primary endpoint, the use of symmetric and asymmetric boundaries in interim analysis, data-driven interim analyses, overruling of a group sequential boundary, comparison of two means and the use of logrank tests in survival trials.
KeywordsTwo one-sided hypotheses testing Alpha and beta spending Sequential boundaries and stopping guidelines Proportional hazards assumption Information scale
Unable to display preview. Download preview PDF.
- 5.Ellenberg S, Fleming T, DeMets D (2002) Data monitoring committees in (clinical trials: a practical perspective). John Wiley & Sons, West Sussex Google Scholar
- 6.East5 Manual (2007) Cytel Inc., Cambridge, MA Google Scholar
- 8.Friedman LM, Furberg CD, DeMets DL (1998) Fundamentals of clinical trials, 3rd edn. Springer, New York Google Scholar
- 17.Pampallona S, Tsiatis AA, Kim K (2001) Interim monitoring of group sequential trials using spending functions for the type I and type II error probabilities. Drug Inf J 35:1113–1121 Google Scholar
- 23.Reboussin DM, DeMets DL, Kim KM, Lan KKG (1995) Programs for computing group sequential bounds using the Lan–DeMets method, version 2.1. UW Department of Biostatistics, Technical Report No. 95, October 1995 Google Scholar
- 25.Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN for the African–American Heart Failure Trial Investigators (2004) Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. NEJM 351(20):2049–2057 CrossRefGoogle Scholar